The Clinical Efficacy of Three Oral Hygiene Regimens Using a Manual Toothbrush, Toothpaste and a Mouthwash in Controlling Dental Plaque and Gingivitis

• ClinicalTrials.gov Identifier: NCT02193165
• Recruitment Status: Completed
• First Posted: July 17, 2014
• Results First Posted: February 6, 2015
• Last Update Posted: August 17, 2015
• Sponsor: Colgate Palmolive
• Information provided by (Responsible Party): Colgate Palmolive

Study Description

Brief Summary:

The objective of this clinical research study is to assess the efficacy of three oral hygiene multi-component regimens encompassing the use of a manual toothbrush, toothpaste and a mouthwash in controlling established dental plaque and gingivitis.

Condition or disease	Intervention/treatment	Phase
Dental Plaque; Gingivitis	Drug: triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash; Drug: stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash; Drug: fluoride toothpaste + fluoride Mouthwash	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 120 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: The Comparative Efficacy of Three Oral Hygiene Multi-component Regimens Encompassing the Use of a Manual Toothbrush, Toothpaste and a Mouthwash in Controlling Established Dental Plaque and Gingivitis.
• Study Start Date: July 2014
• Actual Primary Completion Date: August 2014
• Actual Study Completion Date: August 2014

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Regimen 1; triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash	Drug: triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash; Brush whole mouth with Total toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using a Total 360 toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of mouthwash for 30 seconds.; Other Names: Total toothpaste; Total Mouthwash
Active Comparator: Regimen 2; stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash	Drug: stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash; Brush whole mouth with Crest Pro-Health toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Pro-Health toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health Multi-Protection mouthwash for 30 seconds.; Other Names: Crest Pro-Health toothpaste; Crest Pro-Health Multi-Protection Mouthwash
Placebo Comparator: Regimen 3 - Control group; fluoride toothpaste + fluoride Mouthwash	Drug: fluoride toothpaste + fluoride Mouthwash; Brush whole mouth with Crest Cavity Protection toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Indicator toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health For Me Breezy Mint mouthwash for 30 seconds.; Other Names: Crest Cavity Protection toothpaste; Crest Pro-Health For Me Breezy Mint mouthwash

Outcome Measures

Primary Outcome Measures :

1. Dental Plaque Scores [ Time Frame: Baseline ]
   Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth)
2. Dental Plaque Scores [ Time Frame: 4 weeks ]
   Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth)
3. Dental Plaque Scores [ Time Frame: 6 weeks ]
   Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth)
4. Gingivitis Scores [ Time Frame: Baseline ]
   Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding)
5. Gingivitis Scores [ Time Frame: 4 weeks ]
   Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding)
6. Gingivitis Scores [ Time Frame: 6 weeks ]
   Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding)

Eligibility Criteria

• Ages Eligible for Study: 21 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Male and female subjects, ages 21-70, inclusive.
2. Availability for the six-week duration of the study.
3. Good general health.
4. Minimum of 20 uncrowned permanent natural teeth (excluding third molars).
5. Initial gingivitis index of at least 1.0 as determined by the use of the Loe and Silness Gingival Index.
6. Initial plaque index of at least 1.5 as determined by the use of the Quigley and Hein Plaque Index (Turesky Modification).
7. Signed Informed Consent Form.

Exclusion Criteria:

1. Presence of orthodontic bands.
2. Presence of partial removable dentures.
3. Tumor(s) of the soft or hard tissues of the oral cavity.
4. Advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone).
5. Five or more carious lesions requiring immediate restorative treatment.
6. Use of antibiotics any time during the one month prior to entry into the study.
7. Participation in any other clinical study or test panel within the one month prior to entry into the study.
8. Pregnant women or women who are breast feeding.
9. Dental prophylaxis received in the past two weeks prior to baseline examinations.
10. History of allergies to oral care/personal care consumer products or their ingredients.
11. On any prescription medicines that might interfere with the study outcome.
12. An existing medical condition which prohibits eating or drinking for periods up to 4 hours.
13. History of alcohol or drug abuse

Contacts and Locations

Locations

Puerto Rico

Centro Comercial Plaza Trujillo

Trujillo Alto, Puerto Rico, 00976

Sponsors and Collaborators

Colgate Palmolive

More Information

• Responsible Party: Colgate Palmolive
• ClinicalTrials.gov Identifier: NCT02193165
• Other Study ID Numbers: CRO-2014-07-PG-REG-PR-BS
• First Posted: July 17, 2014
• Results First Posted: February 6, 2015
• Last Update Posted: August 17, 2015
• Last Verified: July 2015

Additional relevant MeSH terms:

Gingivitis; Dental Plaque; Infections; Gingival Diseases; Periodontal Diseases; Mouth Diseases; Stomatognathic Diseases; Dental Deposits; Tooth Diseases; Triclosan; Cetylpyridinium; Fluorides; Tin Fluorides; Cariostatic Agents; Protective Agents; Physiological Effects of Drugs; Anti-Infective Agents, Local; Anti-Infective Agents; Fatty Acid Synthesis Inhibitors; Hypolipidemic Agents; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Lipid Regulating Agents